Literature DB >> 22023453

Hepcidin expression in patients with acute leukaemia.

Pan-Pan Cheng1, Zhen-Zhen Sun, Fang Jiang, Yue-Ting Tang, Xiao-Yang Jiao.   

Abstract

BACKGROUND: Hepcidin plays a central role in iron homeostasis, which is regulated by iron stores, the rate of erythropoiesis, inflammation, and hypoxia. Aberrant expression of hepcidin was found in many diseases, however, there is scant information on hepcidin expression in acute leukemia (AL).
MATERIALS AND METHODS: 32 patients with AL which diagnosis according to FAB criteria were studied. Serum hepcidin levels, erythropoietin (EPO), interleukin-6 (IL-6), hematological parameters, intracellular and extracellular iron store were evaluated.
RESULTS: Hepcidin was elevated significantly with increased iron storage in patients at onset of AL when erythropoiesis was depressed by blast cells, then decreased significantly with AL remission, while soluble transferrin receptor (sTfR) concentration was elevated. Negative correlations were found between serum hepcidin and erythropoietic markers including RBC, Hb, Ret and sTfR. Positive correlations were shown between hepcidin and ferritin, between hepcidin and ratio of sideroblasts, as well as between hepcidin and IL-6.
CONCLUSIONS: Hepcidin production was regulated by iron stores, inflammation and erythropoietic activity in AL patients. Erythropoietic activity may play the main role among the regulators of hepcidin expresssion.
© 2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22023453     DOI: 10.1111/j.1365-2362.2011.02608.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  8 in total

1.  Applied value of monitoring serum hepcidin in differential diagnosis of infection versus tumor fevers.

Authors:  Ling Li; Jiang-Guo Zhang; Man-Zhi Zhao; Zhu-Hua Wu; Jian-Xin Song
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-04-11

2.  Clinical significance of microcytosis in patients with primary myelofibrosis.

Authors:  Paolo Strati; Naveen Pemmaraju; Zeev Estrov; Marylou Cardenas-Turanzas; Sherry Pierce; Kate J Newberry; Naval Daver; Jorge Cortes; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2014-08-28       Impact factor: 3.156

3.  Elevated Hepcidin Is Part of a Complex Relation That Links Mortality with Iron Homeostasis and Anemia in Men and Women with HIV Infection.

Authors:  Peter A Minchella; Andrew E Armitage; Bakary Darboe; Momodou W Jallow; Hal Drakesmith; Assan Jaye; Andrew M Prentice; Joann M McDermid
Journal:  J Nutr       Date:  2015-04-22       Impact factor: 4.798

Review 4.  The Clinical Significance of Iron Overload and Iron Metabolism in Myelodysplastic Syndrome and Acute Myeloid Leukemia.

Authors:  Sarah Weber; Anastasia Parmon; Nina Kurrle; Frank Schnütgen; Hubert Serve
Journal:  Front Immunol       Date:  2021-02-19       Impact factor: 7.561

Review 5.  Iron Dysregulation in Human Cancer: Altered Metabolism, Biomarkers for Diagnosis, Prognosis, Monitoring and Rationale for Therapy.

Authors:  Pierre Lelièvre; Lucie Sancey; Jean-Luc Coll; Aurélien Deniaud; Benoit Busser
Journal:  Cancers (Basel)       Date:  2020-11-26       Impact factor: 6.639

Review 6.  Hepcidin in Children and Adults with Acute Leukemia or Undergoing Hematopoietic Cell Transplantation: A Systematic Review.

Authors:  Artur Słomka; Monika Łęcka; Jan Styczyński
Journal:  Cancers (Basel)       Date:  2022-10-08       Impact factor: 6.575

7.  Chest CT Findings and Differential Diagnosis of Mycoplasma pneumoniae Pneumonia and Mycoplasma pneumoniae Combined with Streptococcal Pneumonia in Children.

Authors:  Jing Wang; Chen Xia; Ashutosh Sharma; Gurjot Singh Gaba; Mohammad Shabaz
Journal:  J Healthc Eng       Date:  2021-06-14       Impact factor: 2.682

Review 8.  Differential regulation of hepcidin in cancer and non-cancer tissues and its clinical implications.

Authors:  Driton Vela; Zana Vela-Gaxha
Journal:  Exp Mol Med       Date:  2018-02-02       Impact factor: 8.718

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.